SVB Leerink Maintains Outperform on Recursion Pharmaceuticals, Raises Price Target to $32
SVB Leerink analyst Mani Foroohar maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Outperform and raises the price target from $30 to $32.
Recursion, Bayer Expand Fibrosis Pact To Include Inferential Search Capabilities
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) expanded its existing strategic collaboration in fibrosis with Bayer AG (OTC:BAYRY). The expanded collaboration will include Recursion’s inferential search…
Recursion And Bayer Expand Fibrosis Collaboration To Include Inferential Search Capabilities
Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, today announced
76 Biggest Movers From Yesterday
Gainers
Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share.
Recursion Pharmaceuticals Q3 EPS $(0.28) Up From $(1.09) YoY, Sales $2.53M Up From $1.02M YoY
Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.28) per share. This is a 74.31 percent increase over losses of $(1.09) per share from the same period last year. The company reported $2.53
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
Recursion Is Granted FDA Fast Track Designation For REC-2282 For The Potential Treatment Of NF2-Mutated Meningiomas
Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that the
Berenberg Initiates Coverage On Recursion Pharmaceuticals with Buy Rating, Announces Price Target of $37
Berenberg analyst Gal Munda initiates coverage on Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy rating and announces Price Target of $37.